arrow
R

Ronald B. Postuma

mcgill university
H指数:89
被引数:4.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A preprocessed multimodal neuroimaging dataset from Quebec Parkinson Network for biomarker discovery

来自魁北克帕金森网络用于生物标志物发现的多模态神经影像预处理数据集

2026-09-110
OAAI
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative

帕金森病诊断前的个体识别与入组:基于生物标志物的适应性资格筛选与入组至帕金森进展标志物倡议

2026-05-140
PRE
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

LRRK2-targeting反义寡核苷酸治疗帕金森病: 1期随机对照试验

2026-03-240
PRE
Estrogen-related receptor gene expression associates with sex differences in cortical atrophy in isolated REM sleep behavior disorder

雌激素相关受体基因的表达与孤立性快速眼动睡眠行为障碍皮质萎缩的性别差异相关

2025-10-100
OAAI
Free water predicts dementia with Lewy bodies in isolated REM sleep behavior disorder

游离水预测了孤立性快速眼动睡眠行为障碍中的路易体痴呆

2025-09-190
OAAI
Quantifying Cognitive Change across One Year in REM Sleep Behavior Disorder: A Preliminary Analysis of North American Prodromal Synucleinopathy (NAPS) Consortium Study.

量化一年内REM睡眠行为障碍中的认知变化:一项北美前驱期突触核蛋白病(NAPS)联盟研究的初步分析。

2025-09-010
PRE
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

作者更正:时间-事件分析缓解了症状性治疗对帕金森病试验中治疗效果的影响。

2025-08-130
OA
Altered network efficiency in isolated REM sleep behavior disorder: A multicentric study

孤立性REM睡眠行为障碍中网络效率的改变:一项多中心研究

2025-08-120
OA
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data
2025-03-010
OAAI
Lack of epistatic interaction of SNCA with APOE in synucleinopathies

帕金森病中SNCA与APOE缺乏表观遗传交互作用

2025-01-010
PRE
IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder
2024-11-010
PRE
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial
2024-10-080
OAAI